The restricted expression pattern of PRAME in normal tissues and its overexpression in tumours renders it a useful marker of minimal residual disease after chemotherapy, and an attractive target for immunotherapy, particularly in acute myeloid leukaemia (AML) and chronic myeloid leukaemia (CML) [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12]. Here, PRAME is linked to acute myeloid leukemia.